Ascletis Pharma unveils promising obesity drug data showing significant weight loss improvements.

Ascletis Pharma announced new data presentations at the 33rd European Congress on Obesity, highlighting their obesity drug candidates. ASC47 combined with semaglutide showed up to 111.8% greater weight loss compared to semaglutide alone. ASC36 demonstrated a much longer half-life and superior weight loss effects in preclinical models compared to existing treatments. These advancements suggest potential new effective therapies for obesity management, with further clinical development anticipated.